



REGIO Evaluation Network

Teleconference 13 May 2020

DG REGIO – B2 Evaluation and European Semester

Agenda


- 1. Introduction + “webex rules” – 14:00 hrs**
- 2. COVID-19 Monitoring: Commission Non-paper – 14:15 hrs**
- 3. 2021-2027: Preparing programming – 15:00 hrs**
 - 3.1 Example of Specific Objective 1.1: template and performance framework methodology
 - 3.2 Reference tables for categorisation and indicators
- 4. Other Business - 15:45 hrs**
 - 4.1 Priorities for next teleconferences

Webex rules

- A meeting unlike our normal meetings. Short interventions to stay to 2 hrs.
- Turn off cameras. All microphones will be muted (large participation expected : avoid background noise)
- You can post questions in the **chat “everyone” function**. Flag the item and your delegation - (i.e. “*Item 2 – IE: question/comment text*”)
- Also post in the chat if you want to speak.
- We will check the questions / comments per item and try to answer “live”.
- In case we do not manage to answer all questions we will regroup questions and answers in the minutes
- **We will record for the purpose of the minutes**

New to Webex?

1. Mute / unmute mic
2. Turn on / off your video
3. View chat window



2. COVID-19: Monitoring the response and outputs 1/7

- High policy / political interest in direct COVID-19 response at Regional, National and EU level
- Existing Intervention fields (053 + 081) and Indicator (CO36) provide limited info on COVID-19 response (See [Open data health story](#))
- Any approach to improving information in shared management must be rapid (i.e. non legislative) and based on close cooperation between EC and Member States + programmes

COVID-19 : Tracking outputs 2/7

- Several MS plan to add programmes specific indicators for new actions targeting the COVID-19 response **to capture outputs**
- REGIO.B2 proposes a **voluntary** list of specific indicators to be used, when relevant. (No amendment to EC legislation)
- It will allow REGIO to make use of the monitoring done by the cooperating programmes
- A wide use of these codes and indicators would be highly valued for accountability, transparency and communication at EU level (and other policy purposes)
- Prepared by DG REGIO + DG EMPL with DG SANTE

COVID-19 : Tracking outputs 3/7

What action is need by programmes?

- Add relevant indicators (**codes and names**) to the programme monitoring system
- Use them in project monitoring
- Include the indicator codes / names / target values (understood as a best estimate) in an OP modification by end 2020
- Report in 2020 AIR (and ad-hoc in national monitoring system)

Commission action:

We would add the list in EN in SFC2014 for ease and consistency of use.

COVID-19 : Tracking outputs 4/7

- ERDF HEALTH specific indicators 1/2

Complement to Intervention Field 053 – Health Infrastructure

Code	Indicator name	Unit
CV1*	Value of personal protective equipment purchased (total public cost)	EUR
CV2*	Value of medical equipment purchased (ventilators, beds, monitors, etc.) (total public cost)	EUR
CV3*	Value of medicines purchased linked to the testing and treatment of COVID-19 (total public cost) (Including cost of testing kits, anti-virals and other consumables)	EUR
CV4*	Value of IT equipment and software/licences financed in COVID-19 response (total public cost)	EUR
	CV4a – Value of COVID-19 related IT for SMEs	EUR
	CV4b – Value of COVID-19 related IT for health	EUR
	CV4c – Value of COVID-19 related IT for education	EUR
CV5	Value of grants for R&D into COVID-19 treatments (medicines) and vaccines (total public cost)	EUR

COVID-19 : Tracking outputs 5/7

- ERDF HEALTH specific output indicators 2/2

Code	Indicator name	Unit
CV6*	Personal protective equipment (PPE) (Including disposable masks, eye protection, coveralls, etc.)	Number of items
CV7	Ventilators to support treatment of COVID-19 (Including CPAP (positive air pressure) devices)	Number of medical devices
CV8	Additional bed space created for COVID-19 patients (Including acute and ICU beds, also in field hospitals)	Bed spaces
CV9	Number of laboratories newly built, newly equipped or with expanded capacity to test for COVID-19	Laboratories
CV10*	Testing capacity supported to diagnose and test for COVID-19 (Including antibody testing)	Number of tests possible
CV11	Ambulances and vehicles purchased for emergency response	Vehicles
CVxx	<i>[Other programme specific COVID-19 health indicators]</i>	

*Indicators also relevant in ESF investment priorities.

COVID-19 : Tracking outputs 6/7

- SME specific indicators

Code	Indicator name	Unit
CV20	Value of non-repayable financial support to SMEs for working capital (grants) in COVID-19 response (total public cost)	EUR
CV21	Value of financial support to SMEs for working capital other than grants (financial instruments) in COVID-19 response (total public cost)	EUR
CV22	Number of SMEs supported with non-repayable financial support for working capital (grants) in COVID-19 response	Enterprises
CV23	Number of SMEs supported with working capital other than grants (financial instruments) in COVID-19 response	Enterprises
CV24	Number of SMEs receiving non-financial support (advice, etc.) in COVID-19 response	Enterprises
CV25	Number of enterprises supported to supply equipment and PPE to the healthcare system	Enterprises
CVxx	<i>[Other programme specific COVID-19 enterprise indicators]</i>	

COVID-19 : Tracking outputs 7/7

- ESF specific indicators

ESF programme specific output indicators

Code	Name	Unit
CV30	Value of ESF actions to combat or counteract the effects of the COVID-19 pandemic (total public cost)	EUR
CV31	Number of participants supported in combating or counteracting the effects of the COVID-19 pandemic	persons
	<i>CVST – Number of participants who benefitted from support in short-time work arrangements</i>	persons
	<i>CVHC – Number of health care personnel who benefitted from ESF support</i>	persons
CV33	Number of entities supported in combating or counteracting the effects of the COVID-19 pandemic	entities

ESF programme specific result indicators

Code	Name	Unit
CVR1	Number of participants maintaining their job 6 months after the end of support ¹	persons
CVR2	Number of participants gaining a qualification upon leaving supported in actions combatting the effects of the COVID-19 pandemic ²	persons

Q+A – COVID-19 - Non Paper

- Speed is of the essence to capture meaningful information
- Definitions are national. EC does not plan to set them.
- **Will the indicators provide sufficient coverage?**
- **Can you use the codes as proposed in the non paper?**
- Q+A?

3. Programming 2021-2027

A word on the 2021-2027 work streams:

- Ongoing: Member States December contributions (#8) are being studied;
- REGIO waiting the results of the Trilogues to produce final indicators fiches (including a renumbering to create a sequential list)
- Ongoing: Finalising the work with Jaspers on the transport result indicators (following the seminar held in February)
- Planned: A seminar (teleconference) with MS on the measurement of GHG emissions (and savings)
- Now: Presentation of example of Specific Objective 1.1

3.1 Specific Objective 1.1 – A stylised example

CONTEXT: [Category of region: More developed] - [Basis for calculation: Public cost]

Policy Objective 1 - SO 1.1 - Enhancing research and innovation capacities and the uptake of advanced technologies

The related types of actions:

- **Action 1.1 Support R&I in SMEs by investing in fixed assets for relevant activities**
- **Action 1.2 Investments in intangible assets in SMEs for activities directly related to R&I**

The main target groups: SMEs

Actions safeguarding equality, etc. :

Specific territories targeted:

Interregional/cross-border/transnational actions:

Use of financial instruments: No

Table 2: Output indicators								
Priority	Specific objective (Jobs and growth goal) or area of support (EMFF)	Fund	Category of region	ID [5]	Indicator [255]	Measurement unit	Milestone (2024)	Target (2029)
<i>PA1</i>	<i>SO1.i</i>	<i>ERDF</i>	<i>More</i>	<i>RCO01</i>	<i>Enterprises supported</i>	<i>enterprises</i>	<i>62</i>	<i>620</i>
<i>PA1</i>	<i>SO1.i</i>	<i>ERDF</i>	<i>More</i>	<i>RCO02</i>	<i>Enterprises supported by grants</i>	<i>enterprises</i>	<i>62</i>	<i>620</i>
<i>PA1</i>	<i>SO1.i</i>	<i>ERDF</i>	<i>More</i>	<i>RCO06</i>	<i>Researchers working in supported research facilities</i>	<i>Annual FTE</i>	<i>36</i>	<i>360</i>

Table 3: Result indicators											
Priority	Specific objective	Fund	Category of region	ID [5]	Indicator [255]	Measurement unit	Baseline or reference value	Reference year	Target (2029)	Source of data [200]	Comments [200]
<i>PA1</i>	<i>SO1.i</i>	<i>ERDF</i>	<i>More</i>	<i>RCR03</i>	<i>SMEs introducing product or process innovation</i>	<i>enterprises</i>	<i>0</i>	<i>2021</i>	<i>450</i>	<i>Monitoring system</i>	
<i>PA1</i>	<i>SO1.i</i>	<i>ERDF</i>	<i>More</i>	<i>RCR102</i>	<i>Research jobs created in supported entities</i>	<i>annual FTE</i>	<i>0</i>	<i>2021</i>	<i>60</i>	<i>Monitoring system</i>	
<i>PA1</i>	<i>SO1.i</i>	<i>ERDF</i>	<i>More</i>	<i>RCR02</i>	<i>Private investments matching public support</i>	<i>Eur</i>	<i>0</i>	<i>2021</i>	<i>147 000 000</i>	<i>Monitoring system</i>	
<i>PA1</i>	<i>SO1.i</i>	<i>ERDF</i>	<i>More</i>	<i>RCR07</i>	<i>Patent applications</i>	<i>patents</i>	<i>0</i>	<i>2021</i>	<i>84</i>	<i>Monitoring system</i>	

Table 4: Dimension 1 – intervention field					
Priority No	Fund	Category of region	Specific objective	Code	Amount (EUR)
PA1	ERDF	More	SO 1.i	002	50,000,000
PA1	ERDF	More	SO1.i	005	60,000,000

Table 5: Dimension 2 – form of financing					
Priority No	Fund	Category of region	Specific objective	Code	Amount (EUR)
PA1	ERDF	More	SO1.i	01	110,000,000

Table 6: Dimension 3 – territorial delivery mechanism and territorial focus					
Priority No	Fund	Category of region	Specific objective	Code	Amount (EUR)
etc					

SO 1.1 – SME R+I – PF Methodology Doc. - 1/4

- **Methodological document (Article 13) is clearly needed to understand**
 - the intervention logic,
 - the use of resources and
 - the choice of indicators by type of intervention.
- The methodological document should present also the evidence which supports the assumptions used for the calculation of the 2024 milestones (for output indicators) and the 2029 targets (for output and result indicators).
 - *For example: the rate of innovation of 90% assumed for action 1.1 can be based on experience from similar interventions in the past programming period, related research or experience from other (similar) regions.*
- The document should also discuss risks (e.g. it should document assumptions around success, durability of interventions, data reliability, etc.)

SO 1.1 – SME R+I – PF Methodology Doc. – 2/4

Action (or measure / scheme) 1: Support to product and process innovation in SMEs

- The action supports investments in fixed assets in R&I activities in SMEs (IF category 002). Total budget EUR 100 million (assumption 50:50)
- The success of the intervention is defined in terms of SMEs introducing product or process innovation as a result of the support.
- The outputs are measured in terms of enterprises supported by grants.
- The 2029 target for RCO02 is based on the assumption of 200 000 euro average support per enterprise (i.e. EUR 100 million / EUR 200 000 = 500 enterprises)
- The 2029 target for RCO01 equals the 2029 target for RCO02
- As regards output milestones for 2024, it is assumed that progress with the action would amount to 10% of the final targets set based on the allocation for 2021-2025 (i.e. $10\% * 500 = 50$ enterprises)
- The 2029 target for RCR02 (private investment) is based on the assumption of 40% private financing under state aid rules (i.e. EUR 100 m public = 60% total => Private = EUR 67 m)
- The 2029 target for RCR03 is based on the assumption of a success rate of innovation of 90%. That is, 90% of all enterprises supported (as reflected by RCO02) will introduce product or process innovation as a result of the support (i.e. $90\% * 500 = 450$ enterprises).

SO 1.1 – SME R+I – PF Methodology Doc. – 3/4

Action (or measure/scheme) 2: Support patentable innovation and SMEs and creation of research jobs in SMEs

- The action provides support for investments in intangible assets for R&I activities through research projects in SMEs (category 005).
- Success is defined in terms of new researchers hired for the work on these projects and the patents submitted by the supported SMEs as a result of the investment. Outputs are measured in terms of enterprises supported by grants and the number of researcher in these SMEs who work in the research projects supported.
- The 2029 target for RCO02 is based on the assumption of 1 million euro average support per enterprise (i.e. EU 120 million/ EUR 1 million = 120 enterprises). The 2029 target for RCO01 equals the 2029 target for RCO02.
- The 2029 target for RCO06 is based on the assumption of, on average, 3 researchers employed per enterprises supported (at the start of the project) (i.e. $3 * 120=360$ FTEs).
- As regards milestones for 2024, it is assumed that progress with the action would amount to 10% of the final targets set based on the allocation for 2021-2025 (i.e. $10% * 120=12$ enterprises).
- The 2029 target for RCR102 is determined based on the assumption that 50% of the enterprises supported by the action will finance, on average, one additional researcher (i.e. $50%*120=60$ FTEs).
- The 2029 target for RCR02 is based on the assumption that the supported enterprises will provide private matching finance of 40% of the total public cost under state aid rules (i.e. EUR 120 million = 60% of total => private = EUR 80 million).
- The 2029 target for RCR07 is based on the assumption that 70% of the supported enterprises will submit patents as a result of the support one year after the (research) output is completed (i.e. $70%*120 = 84$ patents).

Action	Total allocation at action level (indicative)	Indicator		M.U.	Baseline		Milestone 2024	Target 2029	Allocation 2021-2025 used for calculation of 2029 target (euro)	Intervention field	
		Code	Name		Value	Year				Code and name	Amount (EU+National) (euro)
Action 1.1	100,000,000	RCO01	Enterprises supported	enterprises	0	n.a.	50	500	100,000,000	002 - Investments in fixed assets in SMEs directly linked to R&I activities	100,000,000
		RCO02	Enterprises supported by grants	enterprises	0	n.a.	50	500			
		RRCR03	SMEs introducing product or process innovation	enterprises	0	n.a.	n.a.	450			
		RRCR02	Private investments matching	EUR	0	n.a.	n.a.	67,000,000			
Action 1.2	120,000,000	RCO01	Enterprises supported	enterprises	0	n.a.	12	120	120,000,000	005 - Investments in intangible assets in SMEs directly linked to R&I activities	120,000,000
		RCO02	Enterprises supported by grants	enterprises	0	n.a.	12	120			
		RCO06	Researchers working in supported research facilities	annual FTE	0	2021	36	360			
		RRCR102	Research jobs created in supported enterprises	annual FTE	0	2021	n.a.	60			
		RRCR02	Private investments matching public support	EUR	0	n.a.	n.a.	80,000,000			
		RRCR07	Patent applications submitted	patents	0	n.a.	n.a.	84			

Q+A – Specific Objective examples

- Stylised / simple presentation of the programme template + PF methodology
- We expect lots of variety in different programmes
- Is it useful?
- Q+A?

3.2 Draft tables of indicators and categorisation codes

- On CIRCABC : Excel table with the following ***draft*** lists (based on Council texts) to support programme drafting
 - PO / SO Lists
 - Common Output and result indicators
 - Categorisation list for programme templates
- These lists will be adjusted when legislation is finalised (renumbering, renaming, etc.)
- Will be incorporated in test versions of SFC2021 (drop down menus)

Other Business

Priority topics for future teleconferences: Your views ?

1. 2021-2027 more examples of Specific Objectives
2. Evaluation Help desk activities/lessons learned
3. Discussion of requirements on MS impact evaluation: exchange experience on challenges conducting impact evaluations of specific objectives
4. New datasets on Open Data / next generation ODP
5. AIR 2019 preparations; SFC2014 data synchronisation
6. Other issues?

Send comments and questions

- Comments by **22 May** please.
- Mail Box: regio-eval@ec.europa.eu

Thank you and stay safe!